NF2 and ependymoma: To identify potential therapeutic vulnerabilities in the two molecular SP-EPN subtypes, we queried clinical trial databases and literature to select compounds that were currently or recently being investigated in clinical trials for ependymomas or NF2-related schwannomatosis-associated tumors (Fig. 6c).